We have read with interest the letter of Lisowska et al., submitted to Haematologica in response to our manuscript "Macrophages as novel target cells for erythropoietin" by Lifshitz et al., published in Haematologica in June 2010. In their commentary, Lisowska et al. claim that: (1) we have neglected to acknowledge their longstanding contribution in the field of erythropoietin as an immunomodulator, and that (2) we have failed to cite their very recent findings that lymphocytes express EPORs.
We consider it important to respond to their comments and to clarify the relevant points.
1) We have certainly not "passed over the publications of Lisowska et al. concerning immunomodulatory action of recombinant human erythropoietin (rHuEPO) from over the last 12 years" as the authors claim. The scientific work of this group is well recognized by our team and has, in fact, been cited in our previous publications.
1,2 In the article by Prutchi-Sagiv et al. 2005 , 2 we have cited four of their publications [3] [4] [5] [6] clearly mentioning the contribution of these authors to the field of "EPO as an immunoregulator".
Regarding the study of Lisowska et al. demonstrating EPO-Rs on lymphocytes, 7 we did not cite it, simply because it was published after our manuscript in Haematologica had already appeared in the press. Specifically, the issue of EPO-Rs on lymphocytes deserves proper clarification. In the study by PrutchiSagiv et al., 2006 1 we could not determine EPO-R expression on lymphocytes, although we have used most critical methodologies of both PCR and antibody binding, applied on isolated lymphocytes. In our article on these findings we did cite two publications 3,4 of Lisowska et al., reporting on the effect of rHuEPO on cytokine secretion from the lymphocytes. However, it should be noted that in their studies the effect of rHuEPO on cytokine secretion was demonstrated on a heterogeneous cell population (whole blood cell cultures), derived from chronic renal failure patients treated with hemodialysis. we have cited the studies of Bryl 1998 and 1999, 3,4 with respect to their data demonstrating that EPO has the "ability to restore the imbalance of cytokines by decreasing the production of TNF-α and IL-6, resulting in values characteristic of the healthy state". 2) In view of the fact that we could not detect EPO-Rs on lymphocytes and yet the immunomodulatory effects of EPO were obvious, we have proposed a mechanism whereby the effects are exerted via other immune cells, such as dendritic cells and macrophages.
3) The citation in the current manuscript 8 concerning our inability to detect EPO-R on lymphocytes, thus referred to our own previous studies as described by Prutchi-Sagiv et al. 1 This is a legitimate citation, given the fact that the focus of this manuscript was specifically on the function of EPO-R expressed on macrophages.
In summary then, we did refer to publications referred to in Lisowska et al., as far as they were pertinent to our studies and findings, and there was no point in citing them in the particular study which focused on macrophages. 
